sunday 6th september - wrc plc · bruno megarbane, paris, france ps1.6

1

Sunday 7th September 2014 Location

09.00 – 19.30 Registration & Speaker Preview Open

10.00 – 16.00

Parallel Session 1.1 CEC1 – The scope and relevance of immunotoxicology Chairs: Raymond Pieters, Netherlands & Unni Nygaard, Norway PS1.1 – O1 Immunotoxicology of skin sensitisation Ian Kimber, Manchester, UK PS1.1 – O2 Danger of allergic and autoimmune effects of chemicals Raymond Pieters, Utrecht, Netherlands PS1.1 – O3 The chemical and immunological basis of drug hypersensitivity reactions Dean Naisbitt, Liverpool, UK PS1.1 – O4 Developmental immunotoxicology Henk van Loveren, Nilthoven, Netherlands PS1.1 – O5 Immunotoxicology of nanomaterials Unni Nygaard, Oslo, Norway PS1.1 – O6 Immunotoxicology of biologicals Marc Pallardy, Chatenay-Malabry, France

10.00 – 16.00

Parallel Session 1.2 CEC2 – Integrated testing strategies in meeting regulatory information requirements Chair: Kimmo Louekari, Finland PS1.2 – O1 Integrated testing strategies for skin and eye irritation/corrosion Chantra Eskes, Agno, Switzerland PS1.2 – O2 Adverse outcome pathways and their use in the rational design of integrated testing strategies Maurice Whelan, Ispra, Italy PS1.2 – O3 Background and current status of microsampling in the pharmaceutical industry Kathryn Chapman, London, UK PS1.2 – O4 Using QSAR information in integrated testing strategies Tatiana Netzeva, Helsinki, Finland PS1.2 – O5 How can Weight of Evidence analysis/assessment be used in integrated testing strategies Derek Knight, Helsinki, Finland PS1.2 – O6 Integrated testing strategies for reproductive toxicity Aldert Piersma, Bilthoven, Netherlands

2


10.00 – 16.00

Parallel Session 1.3 CEC3 – What is predictive/mechanistic toxicology? From pre-clinical to clinical translation

Chair: Sue Moore, UK

PS1.3 – O1 Translational safety: clinical issue resolution through mechanistic safety Dominique Brees, Basel, Switzerland PS1.3 – O2 Safety: managing the risk/benefit and planning for early clinical development Peter Newham, Macclesfield, UK PS1.3 – O3 Lead optimisation safety hazard identification Sue Moore, Ware, UK PS1.3 – O4 Predictive toxicology: translation from pre-clinical to clinical Colin Fish, Ware, UK PS1.3 – O5 Computational toxicology: a modeller’s perspective Jordi Munoz-Muriedas, Stevenage, UK

10.00 – 16.00

Parallel Session 1.4 CEC4– Emerging innovative methods and technologies for biomonitoring of xenobiotics

Chairs: Jyrki Liesivuori, Finland & Aristidis Tsatsakis, Greece

PS1.4 – O1 Emerging concepts of evidence-based toxicology and ethical issues on biomonitoring and risk assessment Jyrki Liesivuori, Turku, Finland PS1.4 – O2 Nanobiotechnology in food and pharmaceuticals: analysis and emerging safety and health issues Nikos Karamanos, Patras, Greece PS1.4 – O3 Applications of chromatography-mass-spectrometry methods in biomonitoring for occupational exposure Andreas Tsakalof, Larissa, Greece PS1.4 – O4 Oxidative pathways of chemical toxicity modulate extracellular matrix remodelling: potential oxidative stress biomarkers? Dragana Nikitovic, Heraklion, Greece PS1.4 – O5 The interpretation of biomonitoring data using physiologically based pharmacokinetic modelling George Loizou, Buxton, UK PS1.4 – O6 Exposing the exposome: a systems approach for characterising consequences of environmental exposures Martin Wilks, Basel, Switzerland

3


10.00 – 16.00

Parallel Session 1.5 CEC5 – Gender differences in drug metabolism and response Chair: Dieter Schrenk, Germany PS1.5– O1 Gender and species-dependent variation in drug metabolism Speaker TBC PS1.5– O2 Xenobiotic receptors in the gender-specific regulation of drug metabolising enzyme expression in laboratory animals Dieter Schrenk, Kaiserslautern, Germany PS1.5 – O3 In vitro strategies to elucidate the impact of genetic and non-genetic factors on drug metabolism in humans Kathryn Klein, Stuttgart, Germany PS1.5 – O4 Steroids and the sexually dimorphic brain Glenda Gillies, London, UK PS1.5 – O5 Does sex matter? the influence of gender on gastrointestinal physiology and drug delivery Hamid Merchant, Huddersfield, UK

10.00 – 16.00

Parallel Session 1.6 CEC6 – New challenges in toxicity of psychoactive substances Chair: Bruno Megarbane, France PS1.6 – O1 New insights into the mechanisms and management of opioid toxicity Bruno Megarbane, Paris, France PS1.6– O2 Misuse of prescription psychotropic drugs, emerging data from Europe Richard Dart, Denver, USA PS1.6 – O3 Novel sources of data on new psychoactive substance toxicity Peter Hulten, Stockholm, Sweden PS1.6 – O4 An update in the toxicology of stimulant substances Robert Hoffman, New York, USA PS1.6 – O5 An update in the toxicology of novel hallucinogens and synthetic cannabinoids David Wood, London, UK PS1.6 – O6 Inter-individual differences in ethanol toxicokinetics and effects Ana Ferrer-Dufol, Zaragoza, Spain

4


17.00 – 18.30

OPENING CEREMONY Professor Ruth Roberts, President EUROTOX Professor Heather Wallace, President, EUROTOX 2014 EUROTOX Merit Award Keynote Lecture Professor Allister Vale

EICC

18.30 WELCOME RECEPTION & OPENING OF THE EXHIBITION EICC

5

Monday 8th September 2014 Location

08.30 – 09.30 Keynote Lecture Professor C Roland Wolf OBE, University of Dundee, UK The application of transgenic animal models to elucidate human pathways of drug metabolism and chemical toxicity

09.30 – 10.00 Tea/Coffee Break

10.00 – 12.00

Parallel Session 2.1 Symposium 1 – Computational and IT-based toxicology: integration of large multidisciplinary data for hazard identification and characterisation

Chairs: Rob Stierum, Netherlands & Danyel Jennen, Netherlands

PS2.1 – O1 Integration of high-throughput in vitro assays and human exposure modelling for risk-based chemical safety decisions Russell Thomas, North Carolina, USA PS2.1 – O2 Chemical and biological data integration for toxicity and mode-of-action prediction Andreas Bender, Cambridge, UK

PS2.1 – O3 Assuring safety without animal testing concept: integration of in vitro and human disease data to improve toxicology testing Rob Stierum, Utrecht, Netherlands

PS2.1 – O4 Data-integration of endpoints, chemoinformatics and omics Danyel Jennen, Maastricht, Netherlands

PS2.1 – O5 Predictive network modelling with toxicogenomics data Ralf Herwig, Berlin, Germany

10.00 – 12.00

Parallel Session 2.2 Symposium 2 – Receptors at the interplay between endogenous and xenobiotic agonists

Chair: Dieter Schrenk, Germany

PS2.2 – O1 The use of stress response pathway activation for chemical classification Paul Jennings, Innsbruck, Austria

PS2.2 – O2 Nuclear retinoid/retinoid X receptors and their endogenous and xenobiotic ligands in metabolism, differentiation and cancer treatment Julius Brtko, Bratislava, Slovakia

PS2.2 – O3 Arylhydrocarbon receptor (AhR)-dependent and independent effects of dioxin on hepatic and renal gene expression Dieter Schrenk, Kaiserslautern, Germany

PS2.2 – O4 Non-genotoxic hepatocarcinogenic rodent CAR and PPARα activators. What is the human relevance? Brian Lake, Surrey, UK

PS2.2 – O5 Driving CAR (Constitutive Androstane Receptor) to Carcinogenesis: Mechanistic and Practical Implications Jay Goodman

6


10.00 – 12.00

Parallel Session 2.3 Workshop 1 – MicroRNA profiling for biomarker discovery and tissue injury characterisation Chairs: Karol Thompson, USA & Heidrun Ellinger, Germany PS2.3 – O1 The rat microRNA body atlas: towards understanding serum microRNA changes and their utilisation as biomarkers of specific organ toxicity Aaron Smith, Indianapolis, USA PS2.3 – O2 Best practice for measurement of injury-associated microRNAs in biofluids Karol Thompson, Maryland, USA PS2.3 – O3 Global microRNA profiling for biomarker discovery: what is normal? Daniel Tonge, Stoke on Trent, UK PS2.3 – O4 Early microRNA and other non-coding RNA biomarkers for rodent non-genotoxic carcinogens Heidrun Ellinger-Ziegelbauer, Wuppertal, Germany PS2.3 – O5 Investigation of urinary microRNAs associated with segment-specific injury to the nephron Jean-Charles Gautier, Vitry-sur-Seine, France

10.00 – 12.00

Parallel Session 2.4 Workshop 2 – UKEMS/MEG Workshop: Carcinogenic hazards of combustion emissions in traffic pollution

Chairs: Jorn Holme, Norway & Volker Arlt, UK PS2.4 – O1 Air pollution health impacts in 2014 Frank Kelly, London, UK PS2.4 – O2 The problem with diesel Lesley Rushton, London, UK PS2.4 – O3 IARC evaluation of the carcinogenicity of diesel and gasoline engine exhausts Lamia Benbrahim-Tallaa, Lyon, France PS2.4 – O4 The genotoxicity of polycyclic aromatic hydrocarbons found in urban air pollution Alexandra Long, Ontario, Canada PS2.4 – O5 Differential effects of ambient diesel carcinogens on inflammation and DNA damage response in cells relevant for lung toxicity Jorn Holme, Oslo, Norway

7

12.00 – 13.00 13.00 – 14.00

Lunch 'HESI CITE Seminar Series' Advancing scientific innovation towards improved public health Professor Timothy Gant, Head of Toxicology, Centre for Radiation, Chemical, and Environmental Hazards UK

14.00 – 16.00

Exhibition; Posters viewing and discussions at posters

14.00 – 15.30 European Animal Research Association (EARA) 'Animal Research: time to talk'

Kirk Leech Interim Director, European Animal Research Association Dr Giuliano Grignaschi Facilities Manager, Mario Negri Institute, Milan Bella Williams Head of Engagement, Understanding Animal Research

15.30 – 16.00

Tea/Coffee Break

8


16.00 – 18.00

Parallel Session 3.1 Symposium 3 – New approaches to characterising uncertainty in hazard and risk assessment Chair: Carolyn Vickers, Switzerland PS3.1 – O1 The future of the QSAR Toolbox: moving to less uncertainty in predictive toxicology Romualdo Benigni, Paris, France PS3.1 – O2 The WHO guidance on evaluating uncertainties in hazard characterisation: the basic approach Wout Slob, Bilthoven, Netherlands PS3.1– O3 Applying the WHO guidance on evaluating uncertainties in hazard characterisation: a case study on deoxynivalenol Matthias Herzler, Berlin, Germany PS3.1 – O4 DNEL derivation under REACH: assessment factors and dealing with uncertainty Karel de Raat, Helsinki, Finland PS3.1 – O5 EFSA’s approach to characterising uncertainty in risk assessment Andrea Germini, Parma, Italy

16.00 – 18.00

Parallel Session 3.2 Symposium 4 – Cytokine release assays: current practice and interpretation toward clinical translation Chairs: Deborah Finco, USA & Connie Chen, USA PS3.2 – O1

Cytokine release assays: current practice and future directions Deborah Finco, Groton, USA

PS3.2– O2 Cytokine release assays post TGN1412 Richard Stebbings, Middlesex, UK PS3.2 – O3 Advances in the prediction of cytokine release syndrome Kirsty Harper, Huntingdon, UK

PS3.2 – O4 Cytokine release: from laboratory results to clinical manifestations Jaques Descotes, Lyon, France PS3.2 – O5 Regulatory experience with cytokine release testing Gabriele Reichmann, Langen, Germany

9


16.00 – 18.00

Parallel Session 3.3 Workshop 3 – Immunotoxicological safety aspects of biologically engineered proteins

Chairs: Raymond Pieters, Netherlands & Ian Kimber, UK PS3.3 – O1 The immunological bases for protein immunogenicity and allergenicity Ian Kimber, Manchester, UK PS3.3 – O2 Safety assessment of proteins utilised in agricultural biotechnology Gregory Ladics, Wilmington, USA PS3.3– O3 Allergenicity assessment of hydrolysed cow’s milk-based infant formula Leon Knippels, Utrecht, Netherlands PS3.3 – O4 Safety assessment of proteins for therapy of allergy Joost Smit, Utrecht, Netherlands PS3.3 – O5 Risk profiling of biologically-engineered proteins based upon structural and mechanistic homology with the past Erwin Roggen, Lyngby, Denmark

16.00 – 18.00

Parallel Session 3.4 Workshop 4 – Novel aspects of process-generated carcinogens in food

Chairs: Richard Stadler, Switzerland & Dieter Schrenk, Germany PS3.4 – O1 Formation and mitigation of process toxicants in foods Richard Stadler, Vevey, Switzerland PS3.4 – O2 Carcinogenicity and genotoxicity of furan in rats in vivo Angela Mally, Wuerzburg, Germany PS3.4 – O3

Use of omics information in risk assessment of new food risks: proteomics investigations into mechanisms of liver, kidney and testicular toxicity induced by 3-MCPD and its dipalmatate ester in rats Alfonso Lampen, Berlin, Germany

PS3.4 – O4 Epidemiological findings on health risks associated with dietary acrylamide Janneke Hogervorst, Maastricht, Netherlands PS3.4 – O5 Evaluating MoE, and its uncertainty and variability for food contaminants Woodrow Setzer, North Carolina, USA

18.00 – 19.00

EARLY TOXICOLOGISTS EVENING EICC

19.00 – 22.00 AstraZeneca Reception (This is by invitation only)

10

Tuesday 9th September 2014 Location

08.30 – 09.30 Bo Holmstedt Memorial Foundation (BHMF) Lecture Chair: Herman Autrup, Denmark Professor Kevin Park, Centre for Drug Safety Sciences, Liverpool, UK Adverse drug reactions: from man to molecule and back again


10.00 – 12.00

Parallel Session 4.1 Symposium 5– Application of AOP/MOA – based approaches in chemical risk assessment

Chair: Alan Boobis, UK & Marjoke Heneweer, Netherlands PS4.1 – O1 Evolution of mode of action/adverse outcome pathway analyses Bette Meek, Ottawa, Canada PS4.1 – O2 AOP strategy: shaping the future for human health and environmental risk assessment Maurice Whelan, Ispra, Italy PS4.1 – O3 Conduct of mechanistic studies to elucidate modes of action of toxicity according to the IPCS framework document David Rouquie, Sophia Antipolis, France PS4.1 – O4 Applying the skin sensitisation AOP to human health risk assessment Gavin Maxwell, Bedford, UK PS4.1 – O5

Conclusions and discussion Alan Boobis, London, UK

10.00 – 12.00

Parallel Session 4.2 Symposium 6– Nanotoxicology/nanosafety Chairs: Kai Savolainen, Finland & Anne Kahru, Estonia PS4.2 – O1 Understanding the basis of pulmonary toxicity of high aspect respirable particles Craig Poland, Edinburgh, UK PS4.2 – O2 “Safe-by-design” and ” toxic-by design”: two approaches for design of novel functional nanomaterials Kaja Kasemets, Tallinn, Estonia PS4.2 – O3 Markers of oxidative stress are elevated in workers exposed to nanoparticles: 2 year study Daniela Pelclova, Prague, Czech Republic PS4.2 – O4 Ecotoxicological outcomes of nano-biointeractions Anne Kahru, Tallinn, Estonia PS4.2 – O5 New risk assessment concept for engineered nanomaterials required Kai Savolainen, Helsinki, Finland

11


10.00 – 12.00

Parallel Session 4.3 Workshop 5 – Skin sensitisation safety assessment: current perspective on mechanistic steps of induction by hair dyes and its quantification

Chair: Ian Kimber, UK PS4.3 – O1 Mechanistic steps in the immune response to skin sensitising chemicals Ian Kimber, Manchester, UK PS4.3 – O2 Activation and deactivation of aromatic amine hair dyes in the skin Brunhilde Blomeke, Trier, Germany PS4.3 – O3 In vitro sensitisation and primary T cell responses to contact allergens Marc Vocanson, Lyon, France PS4.3 – O4 Induction of skin sensitisation and quantitative risk assessment considerations for hair dyes Carsten Goebel, Darmstadt, Germany PS4.3 – O5 Elicitation of the immune response to hair dye contact allergens in humans Pieter Jan Coenraads, Groningen, Netherlands

10.00 – 12.00

Parallel Session 4.4 Workshop 6 – Weight of Evidence in risk assessment of chemicals

Chair: Christina Ruden, Sweden, Anna Beronius, Sweden PS4.4 – O1 Systematic reviews in health risk assessment of chemicals Annika Hanberg, Stockholm, Sweden PS4.4 – O2 Strength of evidence from theory to practice: identifying the health impacts of environmental chemicals Tracey Woodruff, Oakland, USA PS4.4 – O3 Some approaches to uncertainty in Weight of Evidence and risk assessment Andy Hart, York, UK PS4.4 – O4 Application of the weight of evidence approach in EFSA’s risk assessment of Bisphenol A – was it useful? Anna Castoldi, Parma Italy PS4.4 – O5 Conclusions and discussion – all four speakers

12.00 – 13.00 LUNCH SOT/EUROTOX Debate - Are non-monotonic dose responses at low dose levels toxicologically relevant? Chairs: Peter L. Goering, USFDA, SOT and Arisitidis Tsatsakis, University of Crete, Greece, EUROTOX

12

SOT Debater James C. Lamb, Exponent, Alexandria, VA EUROTOX Debater Dieter Schrenk, Kaiserslautern, Germany

13.00 – 14.00 BTS - ASCEPT Visiting Lecture Professor Nick Buckley, University of Sydney, Australia

Translational toxicology in the developing world

14.00 – 16.00

Hot issues debate Posters viewing & discussions at poster boards

14.00 – 16.00 Microsampling: a paradigm shift in TK sampling maximising the 3Rs benefits of current technology Chair: David Jones, UK Background and current status of micro-sampling in the Pharma Industry: output from NC3Rs workshop and next steps Kathryn Chapman, NC3Rs/ Sue Sparrow GSK Micro sampling in regulatory studies: overcoming the perceived barriers and study design considerations Sally Robinson, AstraZeneca, /Simon Chivers, Novartis Micro-sampling in regulatory studies: practical considerations in sample collection and handling Wesley Dopson, GSK, /Jo Burnett, Covance Bio-analytical considerations in micro-sampling Neil Spooner GSK/ , Amanda Wilson, AZ Reduction of sample volumes for clinical chemistry, haematology and biomarkers Rachel Lawrence, HLS


13


16.00 – 18.00

Parallel Session 5.1 Symposium 7– Translation of in vitro to in vivo translation of concentration-response

Chair: George Loizou, UK PS5.1 – O1 Liver bioreactor as an in vitro metabolism system for quantitative in vitro to in vivo extrapolation Miyoung Yoon, North Carolina, USA PS5.1 – O2 Quantitative in vitro to in vivo extrapolation of stem cell-based toxicity data Jochem Louisse, Wageningen, Netherlands PS5.1 – O3 Computational systems biology for toxicology Pedro Mendes, Manchester, UK PS5.1 – O4 Population-based exposure reconstruction George Loizou, Buxton, UK PS5.1 – O5 Fast identification of xenobiotic metabolites and drug-induced alterations in lipid metabolism Gabriele Cruciani, Perugia, Italy

16.00 – 18.00

Parallel Session 5.2 Symposium 8 – Stem cell differentiation for predicting and evaluating developmental toxicity

Chair: Eugenio Vilanova, Spain PS5.2 – O1 The contribution of toxicology to basic biology and molecular and cell biology to the development of in vitro toxicology testing Eugenio Vilanova, Elche, Spain PS5.2 – O2 Pathway analysis in a human in vitro neurodevelopmental model based on microRNA expression profiling Anna Price, Ispra, Italy PS5.2 – O3 Evaluating developmental toxicity using efficient short term tests based on molecular approaches: the example of chlorpyrifos Miguel Angel Sogorb, Elche, Spain PS5.2 – O4 Human and mouse gene expression pathways of neural embryonic cell differentiation in developmental toxicity David Pamies, Baltimore, USA PS5.2 – O5 A 3-dimensional human embryonic stem cell-derived model to detect neurodevelopmental toxicity of nanoparticles Suzanne Kadereit, Sigmaringen, Germany

14


16.00 – 18.00

Parallel Session 5.3 Workshop 7 – HESI Workshop on neurotoxicity: assessment of neurotoxicity and the use of biomarkers as complementary measures

Chair: Ruth Roberts, UK PS5.3 – O1 Neurotoxicity in drug discovery: importance and assessment Ruth Roberts, Macclesfield, UK PS5.3 – O2 Fluid-based biomarkers in neurotoxicity: molecules, mechanisms and translation into humans Andreas Jeromin, Lexington, USA PS5.3 – O3 Neurobehavioural assessments suitable for inclusion in repeat-dose toxicity studies on candidate drugs Will Redfern, Macclesfield, UK PS5.3 – O4 Magnetic resonance histology G Allan Johnson, North Carolina, USA PS5.3 – O5 Neuropathology endpoints in safety assessment studies Alys Bradley, Edinburgh, UK

16.00 – 18.00

Parallel Session 5.4 Workshop 8 – Aggregate and cumulative risk assessment of chemicals: the example of pesticides

Chairs: Jacob van Klaveren, Netherlands & Angelo Moretto, Italy PS5.4 – O1 The MCRA models and software for cumulative and aggregate risk assessment Hilko van der Voet, Wageningen, Netherlands PS5.4 – O2 EFSA approach to cumulative risk assessment of pesticides

Charlotte Bergkvist, Parma, Italy PS5.4 – O3 Aggregate and cumulative risk assessment of chemicals: the example of pesticides Monika Bross, Limburgerhof, Germany PS5.4 – O4 Integrating in vitro and in vivo data: lessons learned from the ACROPOLIS project Angelo Moretto, Milan, Italy PS5.4 – O5 Enough precision to take a decision: the HESI Risk21 perspective Tim Pastoor, Washington, USA

20.00 – 00.00 Gala Dinner - 50 Year Celebration- Book your tickets early! The National Museum of

Scotland

15

Wednesday 10th September 2014 Location

08.30 – 10.30

Parallel Session 6.1 Symposium 9 - Adaptations in oxidative stress: mechanisms involved Chairs: C Roland Wolf, UK & Demetrios Kouretas, Greece PS6.1 – O1 Application of next-generation reporter mouse models to study stress responses in vivo Michael McMahon, Dundee, UK PS6.1 – O2 Drug induced changes in the mouse liver epigenome Richard Meehan, Edinburgh, UK PS6.1 – O3 The unique mechanisms of whey protein antioxidant activity Demetrios, Kouretas, Thessaly, Greece PS6.1 – O4 Exercise, oxidative stress and hormesis Zsolt Radak, Budapest, Hungary PS6.1 – O5 Cellular responses to oxidative stress: from glutathione to aldehyde dehydrogenases Vasilis Vasiliou, Aurora, USA

08.30 – 10.30

Parallel Session 6.2 Symposium 10 – Environmental epigenetics: implications for in-life and transgenerational toxicity

Chairs: Tim Gant, UK & Kevin Chipman, UK PS6.2 – O1 Epigene-Environment interactions Valentina Bollati, Milan, Italy PS6.2 – O2 Modulation of the epigenome in fish carcinogenesis Leda Mirbahai, Birmingham, UK PS6.2 – O3 The functional ghost in the genome machine: Holistic mapping of environmentally induced changes in the epigenome of a soil sentinel Peter Kille, Cardiff, UK PS6.2– O4 In vitro and lower species models in which to investigate multigenerational effect Claudia Wiegand, Copenhagen, Denmark

16


08.30-10.30 Parallel Session 6.3 Workshop 9– Non-intentionally added substances in food contact materials: how much do we need to know about the unknown? Chair: Hans Ketelslegers, Belgium & Heli Miriam Hollnagel, Switzerland PS6.3 – O1 Non-intentionally added substances in food contact materials: EU regulatory requirements and safety assessment Hans Ketelslegers, Brussels, Belgium PS6.3 – O2 Assessing safety of non-intentionally added substances in polymers used for food contact applications Heli Miriam Hollnagel, Horgen, Switzerland PS6.3 – O3 Paradigm shift to migration-based assessments of intentionally and non-intentionally added substances Beat Brüschweiler, Bern, Switzerland PS6.3 – O4 Non-intentionally added substances: approaches for prioritisation

Lisette Krul, Zeist, Netherlands PS6.3 – O5 Panel discussion

08.30-10.30 Parallel Session 6.4 Workshop 10– From the science of nanotoxicology to regulation Chairs: Frank Le Curieux, Finland & Fabrice Nesslany, France PS6.4 – O1 Toxicology of inhaled nanoparticles Rodger Duffin, Edinburgh, UK PS6.4 – O2 Toxicology of the solid phase: What is so special?

Håkan Wallin, Copenhagen, Denmark PS6.4 – O3 NANOGENOTOX European joint action: what could we learn from all the data? Fabrice Nesslany, Lille, France PS6.4 – O4 Influential factors in nanomaterial genotoxicity induction and testing Shareen Doak, Swansea, UK PS6.4 – O5 Hazard characterisation: specific challenges for nanomaterials/nanoforms in REACH Frank Le Curieux, Helsinki, Finland

10.30-11.00 Tea/Coffee Break

17


11.00-13.00 Parallel Session 7.1 Symposium 11– Towards an integrated approach for the risk assessment of chemical mixtures Chair: Billy Amzal, France PS7.1– O1 Mechanistic approaches for human and ecological risk assessment of chemical mixtures Camille Bechaux, Parma, Italy PS7.1– O2 Physiologically-based toxicokinetic models for prediction of complex metabolic interactions of chemical mixtures Frederic Bois, Verneuil, France PS7.1– O3 New tools for evidence-based risk assessment of chemical mixtures Billy Amzal, Paris, France PS7.1– O4 Harmonisation of ecological and human risk assessment of chemical mixtures Ad Ragas, Nijmegen, Netherlands PS7.1– O5 The relevance of combined action of chemicals through dissimilar modes of action. A science based approach for performing cumulative risk assessment of pesticides residues Andrea Terron, Parma, Italy

11.00-13.00 Parallel Session 7.2 Symposium 12– Target organ toxicity of recreational substances and anabolic drugs Chairs: Félix Carvalho, Portugal & Aristidis Tsatsakis, Greece PS7.2– O1 Involvement of mitochondria in the neurotoxicity of Ecstasy Félix Carvalho, Porto, Portugal PS7.2– O2 Cardiovascular and cardiotoxic actions of sympathomimetic stimulants Kurt Varner, New Orleans, USA

PS7.2– O3 Neurotoxic effect of γ-hydroxybutyic acid: behavioural effects Carmen Pedraza, Malaga, Spain PS7.2– O4 Immunomodulatory effects of anabolic drugs Emanuela Corsini, Milan, Italy PS7.2– O5 Cardiotoxicity of anabolic steroids: animal case study on oral Turinabol and Methandienone Christina Tsitsimpikou, Athens, Greece

18


11.00-13.00 Parallel Session 7.3 Workshop 11– Endocrine disruption: challenges in human health risk assessment using the example of Bisphenol-A Chair: David Bell, Finland PS7.3– O1 EFSA’s risk assessments of BPA, the increasing role of uncertainty Trine Husoy, Oslo, Norway PS7.3– O2 Non-monotonic low-dose effects Gilbert Schönfelder, Berlin, Germany PS7.3– O3 Lifestage-dependent dosimetry and toxicology of BPA in a 90-d rat study and implications for human risk assessment Dan Doerge, Jefferson, USA PS7.3– O4 Integrated testing strategies for reproductive toxicity Aldert Piersma, Bilthoven, Netherlands PS7.3– O5 Low dose effects: the wider consequences for risk assessment Sharon Munn, Ispra, Italy

11.00-13.00 Parallel Session 7.4 Workshop 12– Mechanistic approaches to understanding drug-induced liver injury: IMI’s MIP-DILI project Chair: Nancy Claude, France PS7.4– O1 Predicting drug-induced liver injury: the pharmaceutical industry perspective Richard Weaver, Paris, France PS7.4– O2 Current understanding and new paradigms to tackle DILI prediction Kevin Park, Liverpool, UK PS7.4– O3 Mechanisms and prediction of DILI as revealed from experiments in novel hepatic 3D systems Magnus Ingelman-Sundberg, Stockholm, Sweden PS7.4– O4 Infectious inflammation in DILI Percy Knolle, Bonn, Germany PS7.4– O5 A systems biology approach to unravel the drug-TNFα signaling synergy in idiosyncratic DILI

Bob van de Water, Leiden, Netherlands

13.00-13.30 CLOSING CEREMONY

Professor Aristidis Tsatsakis, President EUROTOX Professor Heather Wallace, President, EUROTOX 2014

sunday 6th september - wrc plc · bruno megarbane, paris, france ps1.6

Documents